BioCentury
ARTICLE | Company News

FDA panel does not back broad reach of Sanofi's dengue vaccine

March 8, 2019 10:15 PM UTC

Sanofi's dengue vaccine did not win the support of an FDA panel for its proposed population of individuals ages 9-45 Thursday, but the panel did back the vaccine's use in adolescents.

The vote came as Sanofi (Euronext:SAN; NASDAQ:SNY) employees and government officials in the Philippines face criminal charges related to the deaths of 10 children allegedly linked to the vaccine, Dengvaxia (see "Sanofi, Government Officials Face Criminal Charges in Philippines for Dengvaxia Deaths")...

BCIQ Company Profiles

Sanofi